Don in Medical Technology

Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute

WASHINGTON, Nov. 24 /PRNewswire-USNewswire/ -- Dear President-Elect Obama: Your first four year Presidential term will start with billions of dollars earmarked for stem cell research. As spokesman for the Repair Stem Cell Institute (RSCI), which is the voice of the Repair Stem C...

West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial

...research and wireless engineering teams to ensure the research devices improve the existing level of care, and are safe, reliable and cost effective. don Jones, vice president of Health and Life Sciences at Qualcomm, and the Institute's chief wireless officer, will lead the integration of wireless techn...

GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting

...pointment of Porter Keadle Moore LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2009. don Hildebrand, company co-founder and Chairman of the Board of Directors, provided opening remarks at the meeting, highlighting significant progress over...

Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders

...ally significant. "We are very pleased with the study results and our recent end of phase II meeting with the Food and Drug Administration," said don Santel, Chief Executive Officer of Hyperion Therapeutics. "We are currently finalizing our phase III study protocol in consultation with the Agency a...

OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications

...l be led by Salah Sedarous, Ph.D., chief technology officer and co-founder, don Morrison, executive vice president of corporate development and Dennis Kush...eb site at: www.omegagenesis.com OmegaGenesis Contact: don Morrison at 408-483-8258 Media Contact: Heidi Chokeir, Ph.D. R...

News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments

...ha, Chief of General Surgery and Program Director, Surgical Oncology Fellowship, McLaren Regional Medical Center, Flint -- don Kooy, President and CEO, McLaren Regional Medical Center -- World Renowned Surgical Oncologists presenting the latest research and ...

Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial

...merica. For further information, please visit http://www.sunshineheart.com or contact: Sunshine Heart: Investor Relations: don Rohrbaugh R.J. Pellegrino Chief Executive Officer The Ruth Group +1 714 259 0732 646-536-7009 d...

(RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa

... Led by don MacKinnon, Founder of HEAR Music NEW YORK, June ...g medicine for those living with AIDS in Africa. don MacKinnon, founder of HEAR Music and former Vice P... concept. "(RED) is such a powerful model," said don MacKinnon, President of (RED) Content. "The world'...

Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles

...cancer that targets only cancer cells, leaving the normal cells intact and functioning. BZL101 is an aqueous extract from herba Scutellaria Barbata D. don of the Lamiaceae family. BZL101 is a compound that induces cell death due to attenuation of mitochondrial transmembrane potential (MTP) leading to the...

Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer

...osomal doxorubicin. "The phase 1 trial in advanced solid tumors showed that both agents could be combined with an acceptable toxicity profile," said don S. Dizon, M.D., assistant professor of obstetrics-gynecology and medicine at the Warren Alpert Medical School of Brown University. "In addition, the r...

Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting

...akhov M, Breitz H, Karlin D, Baker G. General Poster Session: Monday, June 2, from 8 a.m. to 12 p.m. CDT S Hall A1, Poster #14B In addition, don S. Dizon, M.D., assistant professor of obstetrics-gynecology and medicine at the Warren Alpert Medical School of Brown University, will present data f...

GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results

...tional Institutes of Health (NIH). Most recently, GeoVax Senior Vice President of Research & Development, Dr. Harriet Robinson, and President, don Hildebrand, attended a meeting with key HTVN officials in Seattle, Washington to plan and prepare necessary documents for the next phase o...

GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials

...e President of Research & Development, Dr. Harriet Robinson, and President, don Hildebrand, attended a meeting with key HTVN officials in Seattle, Washingt...e previously failed vaccines of Vaxgen and Merck," stated GeoVax President, don Hildebrand. GeoVax has completed two Phase 1 human trials evaluating its ...

Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program

...effective in preventing AIDS." "As a co-founder of GeoVax, Dr. Robinson has been instrumental in the success our company has achieved to date," said don Hildebrand, President, CEO, and Chairman of GeoVax Labs, Inc. "Her leadership in HIV/AIDS vaccine research is invaluable. We believe her contributions...

GeoVax Labs, Inc. Selected by Georgia Bio as '2008 Deal of the Year' Award Winner in Life Sciences Industry

...ie Donald, Michael Hellerstein and Mark Reynolds will receive the award on behalf of the company. GeoVax Vice President Harriet Robinson and President don Hildebrand will not be present as they will be attending a Phase 2 clinical (human) trial planning meeting for their AIDS vaccine with the HVTN (HIV V...

Physicians Will Benefit from Medical Software Advice Website

...for their practices. "The market for medical software is booming, but the software vendor landscape is more fragmented than ever," said don Fornes, founder & Chief Executive Officer of Software Advice. "We aim to bring clarity to the market by matching physicians with the right s...

Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer

... filings with the Securities and Exchange Commission. Halozyme Contact Investor Relations Contact David A. Ramsay don Markley Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8881 (310) 691-7100 dramsay@halozyme.com ...

GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial

... prestigious trial network funded by the US National Institutes of Health. don Hildebrand, GeoVax's President and CEO, commented, "We, along with the rest... for a larger Phase 2 human trial in 2008 For further information, contact don Hildebrand or Jennifer Nelms at (404) 727-0971 or visit http://www.geovax....

Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients

..., future events, or otherwise. CONTACT: Chemokine Therapeutics Corp., Mr. don Evans, Director of Public Relations, Phone: (604) 822-0305 or 1-888-822-030....com">jlongo@equicomgroup.com CONTACT: Chemokine Therapeutics Corp., Mr. don Evans, Director of PublicRelations, Phone: (604) 822-0305 or 1-888-822-0305...

M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data at the AACR Annual Meeting

..., future events, or otherwise. CONTACT: Chemokine Therapeutics Corp., Mr. don Evans, Director of Public Relations, Phone: (604) 822-0305, or 1-888-822-03....com">jlongo@equicomgroup.com CONTACT: Chemokine Therapeutics Corp., Mr. don Evans, Director of PublicRelations, Phone: (604) 822-0305, or 1-888-822-030...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

...NSCLC) -- Robert Raju, M.D.: Pemetrexed (P) in relapsed Small-Cell Lung Cancer (SCLC): Preliminary results of a Phase II trial -- don Richards, M.D., Ph.D.: The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed S...

Remarks by President Bush on Stem Cell Veto and Executive Order

...today. I'm joined on stage by two good docs, really smart, capable people: Dr. Bill Hurlbut, Professor of Stanford University Medical Center; Dr. don Landry, Professor at Department of Medicine -- actually, he's the Chairman of the Department. The reason they're here is these are brilliant biologist...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

... Investor Relations Contact David A. Ramsay don Markley Chief Financial Officer Lippert/Heilshorn & Asso...cer of HalozymeTherapeutics, Inc., +1-858-794-8881, ; or investorrelations, don Markley of Lippert-Heilshorn & Associates, +1-310-691-7100,, for Halozy...